SGLT2 inhibitors are a new class of agents used to treat type 2 diabetes mellitus (T2DM); they reduce glucose reabsorption and thereby reduce blood glucose without stimulating insulin release [1,2]. Here, SLC5A2 is linked to type 2 diabetes mellitus.